PEA for dogs and cats: the companion-animal opportunity
A double-blind, placebo-controlled trial in 50 dogs and 50 cats found 76% of dogs successfully treated against 40% on placebo. That is better controlled evidence than most pet supplement ingredients have — and almost no ingredient supplier is addressing the category.
Published July 2026 by the PEAOID technical team · reviewed against the primary literature
Why PEA makes sense in companion animals
Palmitoylethanolamide is endogenous across mammalian species, not just in humans. Dogs and cats synthesise it, degrade it through the same enzymes, and express the same PPAR-alpha receptor it acts on. There is no interspecies extrapolation problem of the kind that complicates many nutraceuticals moving from human to pet applications.
More usefully, several of the foundational PEA studies were done in canine tissue in the first place. The classic demonstration that PEA inhibits mast-cell mediator release — histamine, prostaglandin D2 and TNF-alpha, dose-dependently across a 10−8 to 10−6 M range — was performed on allergen-challenged canine skin mast cells. The veterinary evidence base is not a borrowed afterthought.
The controlled trial
The category's anchor study is a double-blind, placebo-controlled, randomized clinical trial published in Frontiers in Veterinary Science, testing a bioavailability-enhanced PEA for joint pain in 50 dogs and 50 cats over six weeks, using validated instruments — the Canine Brief Pain Index and the Feline Musculoskeletal Pain Index.
Results
Dogs: 76% classified as successfully treated on PEA against 40% on placebo.
Cats: significant improvement in functional tasks — jumping in particular — and in pain scores at both week 2 and week 6.
Tolerability: well tolerated in both species.
A placebo-controlled trial with validated outcome instruments in both species is a considerably higher standard of evidence than most pet supplement ingredients can point to. The feline data matters especially: cats are pharmacologically awkward, have limited safe analgesic options, and are chronically under-served by the supplement industry.
Where PEA is used in veterinary practice
| Application | Rationale | Evidence |
|---|---|---|
| Osteoarthritis & joint pain | The largest use case in both dogs and cats; ageing populations, limited long-term NSAID options especially in cats. | Controlled trial in 50 dogs and 50 cats. |
| Atopic dermatitis & skin | Mast cells drive canine atopic dermatitis directly. Endogenous PEA and local mast-cell proliferation are both elevated in affected canine skin — a body-own response PEA supplementation can support. | Mechanistic and clinical veterinary literature; ALIAmide reviews. |
| Chronic pain & mobility | A different pharmacological class from NSAIDs and opioids, with a quiet adverse-event record in the published veterinary work. | Extrapolated from the joint trial plus the human literature. |
| Neuroinflammation & cognitive ageing | Canine cognitive dysfunction is an active area; PEA's glial modulation is mechanistically relevant. | Preclinical and mechanistic only. Do not overstate. |
| Equine | Laminitis, joint support and inflammatory conditions in horses. | Limited published work; largely practice-led. |
Dosing in animals
Published veterinary pharmacokinetic work has used doses in the range of 15 to 30 mg/kg in dogs. At 30 mg/kg, ultra-micronized PEA produced roughly a five-fold increase in blood concentration over non-micronized material, with peak plasma levels of 55–60 pmol/mL at one to two hours. At 15 mg/kg, micronized and ultra-micronized gave near-identical peaks — the same diminishing-returns pattern seen in the human data.
Commercial veterinary products generally dose by body-weight band rather than by strict mg/kg. Formulators should note that the practical constraint in this category is usually palatability and chew size rather than dose ceiling.
A necessary caution
Dosing an animal is a veterinary decision. PEAOID supplies raw material to manufacturers; we do not advise on animal dosing regimens and nothing here should be read as doing so. Veterinary product claims are regulated separately from human supplement claims in every market, generally more strictly.
Formats and formulation notes
- Soft chews. The dominant format. Cold-formed chews tolerate normal grade; micronized improves per-piece content uniformity where the chew is small and the dose is tight.
- Powder toppers. Scoop-dosed onto food. Normal or micronized grade. Palatability comes from the carrier, not from PEA, which is essentially tasteless — a genuine advantage in feline products, where palatability failures kill compliance.
- Capsules and tablets. More common in the veterinary-clinic channel than in retail.
- Liquid and oil suspensions. PEA disperses in MCT and similar lipid carriers. Useful for cats and small dogs where dose precision matters.
- Combination products. Frequently formulated with glucosamine, chondroitin, green-lipped mussel, collagen peptides, omega-3 and boswellia in joint positioning.
Two practical points. PEA is odorless and effectively tasteless, so it does not create the palatability problems that many joint actives do — this is a real formulation advantage in cats. And milled PEA has low bulk density, which affects chew volume and mixing behavior; ask for bulk and tapped density data before you design the die.
Why this category is under-supplied
Two things are true about veterinary PEA at once. It has better controlled evidence than most pet supplement ingredients. And almost no ingredient supplier has a page addressing it.
Search the major PEA ingredient suppliers and you will find human nutraceutical positioning, occasionally a line item mentioning pets, and essentially no technical content aimed at a pet-nutrition formulator or a veterinary product developer. Meanwhile the demand side is already there: veterinary teaching resources and clinic networks publish educational material on ultra-micronized PEA, boutique veterinary brands sell it, and practitioners recommend it.
That gap between a real evidence base, real practitioner awareness and near-zero supplier-side engagement is unusual, and it will not last. For a manufacturer looking at where to build next in companion-animal nutrition, it is one of the cleaner opportunities in the category.
Talk to us about pet-grade PEA
References
- Levagen+ (palmitoylethanolamide) alleviates joint pain and reduces the impact of joint pain in canines and felines: a double-blind, placebo-controlled, randomized clinical trial. Front Vet Sci 2026. frontiersin.org
- Gugliandolo E, Peritore AF, Piras C, Cuzzocrea S, Crupi R. Palmitoylethanolamide and related ALIAmides: prohomeostatic lipid compounds for animal health and wellbeing. Vet Sci 2020;7(2):78.
- Palmitoylethanolamide and related ALIAmides for small animal health: state of the art. Biomolecules 2022;12(9):1186.
- Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Vet Res.
- Cerrato S, et al. Canine pharmacokinetics of ultramicronized PEA, 2012; Della Valle F, et al., 2013 — summarized in Beggiato S, Tomasini MC, Ferraro L, Front Pharmacol 2019;10:821.
- Clayton P, et al. Palmitoylethanolamide: a natural compound for health management. Int J Mol Sci 2021;22(10):5305.
Request a specification, a sample, or a quotation
Send us your target dose, format and volume. Our technical team replies with a full documentation pack — specification, method summary, batch CoA and regulatory dossier — within one business day.